[Edaily Reporter Kwon Oh Seok ] MedPacto, Inc.(235980)announced on the 18th that it has submitted an application to the U.S. Food and Drug Administration (FDA) for approval of an amendment to its Investigational New Drug (IND) application for a Phase 1/2 clinical trial of Bactosetip monotherapy in patients with recurrent, refractory, or progressive osteosarcoma.
Disclosure Plus
MedPacto, Inc. Submits Application to U.S. FDA for Approval of Amended Phase 1 and 2 Clinical Trial Protocol for Baektoxetip Monotherapy
Kwon Oh Seok
2026-09-18 18:07:35
Economy
Corporation
IT·Science
Economy
"Home Economy" Expo, AI Festa, and Other Major Events This Week
The BeLT, the tourism and MICE news team of the comprehensive daily economic newspaper E-Daily, presents a variety of news from the domestic and international MICE (Meetings, Incentives, Conventions, …
Corporation
“I Took on the Challenge with the Mindset of a CEO”… The Secret to Success for CJ CheilJedang Corp’s New Marketers
“Product Marketing (PM) is not just a ‘marketer’ but more like a ‘mini-CEO’ who takes full responsibility for a single product.”At CJ CheilJedang Corp(097950), one of Korea’s leading food companies, t…
IT·Science
The Path for “Once-a-Month Weight-Loss Drugs” Widens… Viking’s Success Puts Korean Long-Acting Drug Industry on Edge
U.S.-based Viking Therapeutics has proposed the possibility of a once-monthly weight-loss drug without the need for a separate long-acting formulation technology. From the perspective of domestic deve…
